| vitamin d-resistant rickets | <radiology> X-linked recessive, defect in renal tubular resorption of phosphate, presents at 1 yr, progressive limb deformities X-ray: less severe changes than other rickets, presents later Differential diagnosis features: family hx, normal serum calcium, marked hypophosphataemia (decreased PO4), no secondary hyperparathyroidism (12 Dec 1998) |
|---|---|
| resistant | Making or having powers of resistance, resisting. (18 Nov 1997) |
| resistant ovary syndrome | <syndrome> An obsolete term for amenorrhoea associated with hypergonadotrophism and normal ovarian follicles. Synonym: resistant ovary syndrome. Origin: after the surname of the first reported patient (05 Mar 2000) |
| tartrate-resistant acid phosphatase | <biochemistry, enzyme> Acid phosphatase is present in bone, prostate, platelets, erythrocytes and spleen. Osteoclasts contain an isoenzyme that is resistant to tartrate, whereas, the isoenzyme in the prostate is sensitive. Tartrate-resistant acid phosphatase is elevated in the serum of patients with primary hypoparathyroidism, Paget disease, vertebral osteoporosis, T-cell lymphoma and in women after oophorectomy. Oestrogen replacement in osteoporotic postmenopausal women is associated with a decrease in tartrate-resistant acid phosphatase of 70% over 3 to 6 months. Acronym: TRAP (16 Dec 1997) |
| tuberculosis, multidrug-resistant | Tuberculosis resistant to chemotherapy with two or more antitubercular agents. The problem of resistance is particularly troublesome in tuberculosis as an opportunistic disease in HIV infection. (12 Dec 1998) |
| ketosis-resistant diabetes | Type II or adult onset diabetes mellitus, in which episodes of ketoacidosis rarely occur. (05 Mar 2000) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |
| rational drug design | <pharmacology> Modeling the molecular structure of the target of a drug, for example, an antigen, and then designing a drug that will attack it. (17 Dec 1997) |
| receptors, drug | Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behaviour of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified. (12 Dec 1998) |